Compare Direxion Daily TSLA Bull 2X Shares (TSLL) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily TSLA Bull 2X Shares vs 10X Genomics Inc — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $10.48 (market cap $3.97B), while 10X Genomics Inc trades at $81.27 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 2.5× Direxion Daily TSLA Bull 2X Shares's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily TSLA Bull 2X Shares for 15 Days and 10X Genomics Inc for 91 Days on average.
| TSLL | TXG | |
|---|---|---|
Market Cap | $3.97B | $10.07B |
Volume | 38,458,237 | 5,657,286 |
Sector | Leveraged / Inverse | Health |
52-Week High | $23.03 | $97.74 |
52-Week Low | $6.74 | $11.48 |
Typical Hold Time | 15 Days | 91 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $10.43, up 2.76% with neutral technical signals. The leveraged ETF tracks Tesla's daily performance, showing recent strength tied to Tesla's Cybercab event anticipation. Moving averages indicate bullish momentum while oscillators remain neutral, with RSI suggesting potential overbought conditions at shorter timeframes.
As a leveraged ETF, TSLL carries amplified risk from Tesla's volatility and daily reset mechanics. Recent news highlights both opportunity from Tesla catalysts and structural risks where investors can lose money even when Tesla rises. The ETF's performance depends entirely on Tesla's stock movement and market sentiment toward electric vehicle innovation.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
